Reviva Pharmaceuticals Holdings, (id:5581 RVPH)
1.14 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 10:05:41 AM)
Exchange closed, opens in 1 day 23 hours
About Reviva Pharmaceuticals Holdings,
Market Capitalization 41.47M
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Headquarters (address) |
10080 N. Wolfe Road Cupertino 95014 CA United States |
Phone | 408-501-8881 |
Website | https://www.revivapharma.com |
Employees | 15 |
Sector | Healthcare |
Industry | Biotechnology |
Ticker | RVPH |
Exchange | NASDAQ Stock Exchange |
Currency | USD |
52 week range | 0.600 - 5.67 |
Market Capitalization | 41.47M |
P/E trailing | -0.691 |
P/E forward | -1.53 |
Price/Book | 6.05 |
Beta | -0.055 |
EPS | -1.08 |
EPS United States (ID:6, base:3400) | 24.26 |